Chen Yuan, Chen Xianglei, Pan Lili, Huang Yuanmao, Cai Yuanhua, Li Jinggang, Li Yang, Wang Shaoyuan
Union Clinical Medical College, Fujian Medical University, Fuzhou, China.
Department of Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Xinquan Road, No.29, Fuzhou, Fujian, China.
Cancer Cell Int. 2022 Feb 22;22(1):92. doi: 10.1186/s12935-021-02426-5.
DHX15 is one of the RNA helicase family members involving in several biological processes. Studies have reported that overexpression of DHX15 is related to cancer progression. However, the role of DHX15 in Burkitt lymphoma (BL) and latent Epstein-Barr virus (EBV) infection remains to be elucidated.
Expression of DHX15 was measured in BL patient by immunohistochemical staining. In vitro study, a CCK-8 assay was used to analyze cell proliferation and flow cytometry was performed to assess cell cycle, apoptosis and mitochondria membrane potential. Members of NF-κB signaling pathway and apoptotic-related proteins expression were measured by western-blot. EBV latent infection products and RNA polymerase III transcripts expression were determined by quantitative real-time PCR and western-blot. In vivo study, HE, IHC, TUNEL and ISH assays were used to analyze the effect of DHX15 on subcutaneous tumor nodes formation.
DHX15 was overexpressed in Burkitt lymphoma patients and tends to be associated with poor progression-free survival and poor overall survival. Knockdown of DHX15 significantly inhibited BL tumor growth, reduced cell proliferation, induced cell cycle arrest and increased cell apoptosis. Further analysis showed that canonical NF-κB signaling and its downstream targets, mitochondria and Caspase were involved in the increased cell apoptosis after DHX15 gene knockdown. Furthermore, knockdown of DHX15 reduced EBV latent infection products expression and inhibited RNA polymerase III activity.
DHX15 may be an oncogene in the development of BL and a potential therapeutic target for the treatment of BL and latent EBV infection.
DHX15是RNA解旋酶家族成员之一,参与多种生物学过程。研究报道,DHX15的过表达与癌症进展相关。然而,DHX15在伯基特淋巴瘤(BL)和潜伏性爱泼斯坦-巴尔病毒(EBV)感染中的作用仍有待阐明。
通过免疫组织化学染色检测BL患者中DHX15的表达。在体外研究中,采用CCK-8法分析细胞增殖情况,并进行流式细胞术以评估细胞周期、凋亡和线粒体膜电位。通过蛋白质免疫印迹法检测NF-κB信号通路成员和凋亡相关蛋白的表达。通过定量实时PCR和蛋白质免疫印迹法测定EBV潜伏感染产物和RNA聚合酶III转录本的表达。在体内研究中,采用苏木精-伊红染色(HE)、免疫组织化学染色(IHC)、末端脱氧核苷酸转移酶介导的缺口末端标记法(TUNEL)和原位杂交(ISH)分析DHX15对皮下肿瘤结节形成的影响。
DHX15在伯基特淋巴瘤患者中过表达,且往往与无进展生存期差和总生存期差相关。敲低DHX15可显著抑制BL肿瘤生长,降低细胞增殖,诱导细胞周期停滞并增加细胞凋亡。进一步分析表明,经典的NF-κB信号通路及其下游靶点、线粒体和半胱天冬酶参与了DHX15基因敲低后细胞凋亡增加的过程。此外,敲低DHX15可降低EBV潜伏感染产物的表达并抑制RNA聚合酶III的活性。
DHX15可能是BL发生发展中的一个癌基因,是治疗BL和潜伏性EBV感染的潜在治疗靶点。